Paper Details

  1. Home
  2. Paper Details

Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.

Author: , ArcherDavid F, BalserJohn, BeauregardAdam, CôtéIsabelle, DerogatisLeonard, FrenetteLouise, KoltunWilliam, LabrieFernand, LavoieLyne, MartelCéline, MontesinoMarlene, MoyneurÉrick, ParentJulie, PortmanDavid, VachonAndrée, VaillancourtMario, YoungDouglas

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Daily intravaginal DHEA was found to improve all six domains of female sexual function, including desire, arousal, lubrication, orgasm, satisfaction, and pain at sexual activity, over placebo in a placebo-controlled, prospective, double-blind and randomized study. The total Female Sexual Function Index (FSFI) score showed a 41.3% greater change in the DHEA group than placebo. The study confirmed the previously observed benefits of intravaginal DHEA on female sexual dysfunction and demonstrated that the effects were exerted exclusively at the level of the vagina without any significant changes in serum steroid levels.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: Previous data have shown that intravaginal dehydroepiandrosterone (DHEA, prasterone) improved all the domains of sexual function, an effect most likely related to the local formation of androgens from DHEA. AIMS: To confirm in a placebo-controlled, prospective, double-blind and random...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/26597311

データ提供：米国国立医学図書館（NLM）

Sexual Dysfunction in Postmenopausal Women: A Desert Oasis of Intravaginal Prasterone

The study explores the challenging world of sexual dysfunction in postmenopausal women, a condition that can significantly impact quality of life. Like a camel navigating the treacherous dunes of a desert, the researchers explore the effectiveness of intravaginal prasterone (DHEA) for managing this condition, seeking to alleviate the symptoms and improve sexual function for those affected. This research meticulously examines the evidence for the efficacy of intravaginal prasterone for sexual dysfunction in postmenopausal women, offering valuable insights for navigating this sensitive and often difficult terrain.

Intravaginal Prasterone: A Potential Oasis for Sexual Dysfunction

The findings suggest that intravaginal prasterone may offer significant benefits for managing sexual dysfunction in postmenopausal women with vulvovaginal atrophy (VVA), potentially improving multiple domains of sexual function, including desire, arousal, lubrication, orgasm, satisfaction, and pain during sexual activity. This research offers valuable insights for women navigating the challenges of sexual dysfunction, providing information on a potential treatment option that could improve their quality of life.

Navigating the Desert of Menopause: A Guide for Women

The study underscores the importance of seeking professional guidance for managing sexual dysfunction in postmenopausal women, emphasizing the need for a tailored approach based on individual needs and circumstances. Like a desert guide, this research provides valuable insights for women navigating the challenges of menopause, offering a roadmap for seeking effective treatment and managing the symptoms of this natural transition.

Dr.Camel's Conclusion

This study explores the potential of intravaginal prasterone as a treatment option for sexual dysfunction in postmenopausal women with vulvovaginal atrophy, suggesting that it may offer significant benefits for improving multiple domains of sexual function and quality of life. While further research is needed to confirm its long-term efficacy and safety, the findings provide valuable insights for women navigating the challenges of menopause. It emphasizes the importance of seeking professional guidance and exploring treatment options that are tailored to individual needs and circumstances.
Date :
  1. Date Completed 2016-05-18
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

26597311

DOI: Digital Object Identifier

S1743-6095(16)30012-1

Related Literature

Article Analysis
・Effects of prasterone vaginal
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.